Journal
EUROPEAN HEART JOURNAL
Volume 33, Issue 22, Pages 2821-2830Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehs274
Keywords
Atrial fibrillation; Anticoagulation; Stroke prevention; Bleeding; Apixaban
Categories
Funding
- Bristol-Myers Squibb
- Pfizer
- BMS
- Sanofi-aventis
- Cardiome
- BI
- Johnson Johnson
- St Jude Medical
- Boehringer Ingelheim
- Merck/Schering-Plough
- Regado Biosciences
- AstraZeneca
- Ortho-McNeil-Janssen Pharmaceuticals
- PolyMedix
- Bayer
- DaiichiSankyo
- Bristol-Myers Squibb/Pfizer
- Astellas
- GlaxoSmithKline
- Medtronic foundation
- Merck
- Medicine's Company
- Lilly
- Hoffman-La Roche
- Novartis
- Otsuka
- Schering-Plough
- Medtronic
Ask authors/readers for more resources
Atrial fibrillation (AF) is common among patients with impaired renal function. Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with warfarin and reduced the rate stroke, death and bleeding in the ARISTOTLE trial. We evaluated these outcomes in relation to renal function. Baseline glomerular filtration rate (GFR) was estimated using the CockcroftGault and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations as well as cystatin C measurements. According to baseline CockcroftGault, there were 7518 patients (42) with an estimated GFR (eGFR) of 80 mL/min, 7587 (42) between 50 and 80 mL/min, and 3017 (15) with an eGFR of 50 mL/min. The rate of cardiovascular events and bleeding was higher at impaired renal function (80 mL/min). Apixaban was more effective than warfarin in preventing stroke or systemic embolism and reducing mortality irrespective of renal function. These results were consistent, regardless of methods for GFR estimation. Apixaban was associated with less major bleeding events across all ranges of eGFRs. The relative risk reduction in major bleeding was greater in patients with an eGFR of 50 mL/min using CockcroftGault {hazard ratio (HR) 0.50 [95 confidence interval (CI) 0.380.66], interaction P 0.005} or CKD-EPI equations [HR 0.48 (95 CI 0.370.64), interaction P 0.003]. In patients with AF, renal impairment was associated with increased risk of cardiovascular events and bleeding. When compared with warfarin, apixaban treatment reduced the rate of stroke, death, and major bleeding, regardless of renal function. Patients with impaired renal function seemed to have the greatest reduction in major bleeding with apixaban.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available